Pharma to Test if DMT Helps Brain Regain Function Post Stroke
Source: Streetwise Reports  (1/28/22)
During Streetwise Live! on Jan. 27, 2022, representatives of Algernon Pharmaceuticals discussed the use of the psychedelic DMT in stroke sufferers. On the broadcast were Algernon CEO Christopher Moreau and consultants to the firm, Dr. David Nutt and Dr. Rick Strassman. More >

Co. Meets Goals in COVID Drug Trial
Source: Streetwise Reports  (1/28/22)
Todos Medical has closed a Phase 2 trial of its antiviral 3CL protease inhibitor Tollovir after getting positive interim data. More >

FDA Approves First Tubeless Insulin Delivery Device
Source: Streetwise Reports  (1/28/22)
Shares of Insulet Corp. traded 15% higher after the company reported its Omnipod® 5 automated insulin delivery system has received clearance from the U.S. FDA. The Omnipod® 5 is the first tubeless system to be monitored and controlled remotely using a smartphone. More >

Read Why These 3 Institutions Like This Water Tech Co.
Source: Streetwise Reports  (1/26/22)
Forward Water Technologies Corp. is exploring applications for its forward osmosis water technology in the lithium extraction industry. More >

Possible Treatment for CRC Shows Promise
  (1/25/22)
New trial results of Exelixis' cabozantinib in colorectal cancer are encouraging for further development of the biopharma's XL902 in the indication, noted an H.C. Wainwright & Co. report. More >

Co. Looks to New Structures of Psychedelic Drug for Strokes
Source: Streetwise Reports  (1/25/22)
Algernon Pharmaceuticals Inc. has included novel salt forms of a psychedelic drug being investigated to combat strokes in its intellectual property applications. More >

Bone Cancer Drug Meets Goals, Stocks Rise
Source: Streetwise Reports  (1/25/22)
Shares of Sierra Oncology Inc. traded 48% higher after the company reported that topline data obtained during its Pivotal Phase 3 MOMENTUM Myelofibrosis Study showed that its momelotinib produced statistically significant improvements in anemia and splenic size. More >

FDA Gives Fast Track Status to Firm for Adrenal Rescue Pen
  (1/24/22)
Now with fast track status and positive Phase 1 study results, Antares Pharma plans to advance its ATRS-1902 product candidate into a second trial in Q2/22, noted a Ladenburg Thalmann report. More >

Fourth COVID-19 Vaccine Shot Shown Less Effective
  (1/24/22)
BioNTech aims to develop a COVID-19 vaccine targeting the Omicron variant, noted an H.C. Wainwright & Co. report. More >

‘Strong Data’ Expected From Todos Medical Data Lock
Source: Vision and Value  (1/24/22)
Todos Medical is set to take on the dominant players in oral antivirals for mild to moderate COVID-19, Pfizer Inc. and Merck & Co. Inc., with "strong data" expected to be released soon for its drug Tollovir. More >

GNC to Distribute Products for CBD Co.
  (1/22/22)
The agreement with GNC is a step toward Charlotte's Web Holdings' goals of expanding consumer access to its products and becoming cash flow positive this year, noted a ROTH Capital Partners report. More >

First NSCLC Patient Dosed With Trial Therapeutic
  (1/22/22)
Two recent Vaccitech events, the MAGE trial initial dosing and the acquisition of Avidea's SNAPvax technology, bode well for its ChAdOx1-MVA platform, noted an H.C. Wainwright & Co. report. More >

Fund Triples Holding of Drug Repurposing Firm
Source: Streetwise Reports  (1/20/22)
Several events slated to happen this year could boost Algernon Pharmaceuticals' share price, noted an AlphaNorth Partners Fund performance report. More >

US Cannabis Firm in 'State of Flux'
  (1/19/22)
With several market factors working against Stem Holdings, its future is uncertain, noted a Noble Capital Markets report. More >

Belgium Firm to Buy Epilepsy-Focused Biopharma Co. for $1.9B
Source: Streetwise Reports  (1/19/22)
Shares of Zogenix Inc. rose by 66% after the company reported it entered into an agreement to be acquired by UCB. S.A. of Belgium for $26.00 per share in cash. The offer includes the potential for an additional $2.00 per share if a specific drug approval milestone is met. More >

Biotech Could Launch Trial of Polyp Screening Test in March
  (1/18/22)
The start of the C-Scan study would be a major milestone for Check-Cap, noted an H.C. Wainwright & Co. report. More >

Derm Biopharma Named Top Growth Pick For 2022
  (1/18/22)
Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report. More >

This Pharmaceutical Company Has a Brilliant Concept
Source: Penny Queen  (1/17/22)
Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company. More >

Ph1 Trial Results of Dementia Drug Positive
  (1/12/22)
Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report. More >

Cell Firm Joins With Food Co. to Create Meat Substitute
  (1/12/22)
Pluristem Therapeutics and Tnuva will incorporate a new company that will use its own funding and resources to develop cell-based synthetic meat products, noted a Dawson James Securities report. More >

Vaccine Maker Doses 1st Patient in Phase 1b Parkinson's Trial
Source: Streetwise Reports  (1/12/22)
Shares of new class synthetic vaccine developer Vaxxinity Inc. traded 23% higher after the company reported it has dosed the first patient in its Phase 1b UB-312 Parkinson's disease study. More >

Biotech Co. Partners With Life Sciences Firms
  (1/11/22)
2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report. More >

HealthCare Solutions Co. Gains 8 Million New Members in 2021
Source: Streetwise Reports  (1/11/22)
Accolade Inc. shares rose 27% after the company reported Q3/22 financial results that included a 117% increase in YoY revenue. The firm highlighted that in calendar year 2021, its membership increased four-fold from 2 million to 10 million. More >

2022 to Be Catalyst Rich for Biopharma
  (1/10/22)
The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report. More >

Enrollment Done for COVID-19 Drug Trial
  (1/10/22)
Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report. More >